Skip to main content
Premium Trial:

Request an Annual Quote

Beckman Coulter, Oxford BioMedica, Sigma-Aldrich, GSK, Transinsight, Max Planck

Beckman Coulter Closes $235M Offering; Will Pay Off Debt Tied to Lumigen Buy
Beckman Coulter closed its tender offer for $235 million in senior notes, the company said this week.
The company said the money raised from the offering would go toward paying debts, a large chunk of which comes from its $185 million acquisition of Lumigen in October. Beckman said it would use the rest of the funds to fund research.
The 7.45-percent notes are due 2008, and were offered on Dec. 11 as part of a $600 million offering.
Beckman said it intends to pay a purchase price of $1,025.74, plus $21.94 in interest, per every $1,000 in notes purchased after the offer, and plans to redeem $4.9 million in outstanding notes after indenture.

Oxford BioMedica, Sigma-Aldrich License LentiVector Tech to GSK
Oxford BioMedica and Sigma-Aldrich said this week that they have signed a joint license agreement giving access to their LentiVector gene-delivery technology to GlaxoSmithKline for research purposes.
Financial terms of the deal were not disclosed.
LentiVector was developed by Oxford BioMedica, which signed on Sigma-Aldrich as its strategic partner and exclusive licensee for commercialization of the technology in the research field, according to the companies.

Transinsight Partners with Max Planck on Biomedical Image Searching
Transinsight, a bioinformatics startup based in Dresden, Germany, said this week that it has entered a three-year collaboration with the Max Planck Institute of Molecular Cell Biology and Genetics in the area of biomedical image analysis.
Transinsight said that it plans to extend its GoPubMed search engine “towards biomedical image search and knowledge-based image recognition.” The company said that it plans to focus on “particle tracking imagery produced by high-throughput microscopy.”
Marino Zerial, MPI-CBG director, said in a statement that “it is essential to be able to extract more information from the new generation of image-based screens.”
Transinsight was founded in late 2005. The company has raised seed financing from the German High-Tech Gründer Fonds and an additional undisclosed amount from a private investor.

The Scan

Study Tracks Off-Target Gene Edits Linked to Epigenetic Features

Using machine learning, researchers characterize in BMC Genomics the potential off-target effects of 19 computed or experimentally determined epigenetic features during CRISPR-Cas9 editing.

Coronary Artery Disease Risk Loci, Candidate Genes Identified in GWAS Meta-Analysis

A GWAS in Nature Genetics of nearly 1.4 million coronary artery disease cases and controls focused in on more than 200 candidate causal genes, including the cell motility-related myosin gene MYO9B.

Multiple Sclerosis Contributors Found in Proteome-Wide Association Study

With a combination of genome-wide association and brain proteome data, researchers in the Annals of Clinical and Translational Neurology tracked down dozens of potential multiple sclerosis risk proteins.

Quality Improvement Study Compares Molecular Tumor Boards, Central Consensus Recommendations

With 50 simulated cancer cases, researchers in JAMA Network Open compared molecular tumor board recommendations with central consensus plans at a dozen centers in Japan.